本文關(guān)鍵詞：復(fù)方益肝靈預(yù)防抗結(jié)核藥物致肝損傷的臨床療效分析　出處：《臨床醫(yī)學(xué)研究與實(shí)踐》2016年24期 　論文類型：期刊論文

  更多相關(guān)文章： 復(fù)方益肝靈 肝損傷 抗結(jié)核藥物

【摘要】：目的研究復(fù)方益肝靈預(yù)防抗結(jié)核藥物致肝損傷的臨床療效。方法選取我中心2015年4月至2015年6月管理的80例結(jié)核病患者作為本次試驗(yàn)的研究對(duì)象,將參與試驗(yàn)的患者分為兩個(gè)不同的小組,分別將其定義為對(duì)照組以及研究組,每個(gè)組別的患者均為40例。對(duì)照組患者應(yīng)用一般的藥物進(jìn)行治療,研究組患者采取復(fù)方益肝靈藥劑對(duì)患者進(jìn)行抗肝損傷治療,治療后,比較兩個(gè)組別患者的臨床療效。結(jié)果治療后,研究組肝功能指標(biāo)明顯優(yōu)于對(duì)照組,研究組ALT、AST及TBIL水平均明顯低于對(duì)照組,差異具有統(tǒng)計(jì)學(xué)意義(P0.05)。研究組未表現(xiàn)出明顯的不良反應(yīng),對(duì)照組出現(xiàn)1例乏力,差異無(wú)統(tǒng)計(jì)學(xué)意義(P0.05)。研究組肝功能損傷的發(fā)生率明顯低于對(duì)照組,差異具有統(tǒng)計(jì)學(xué)意義(P0.05)。結(jié)論復(fù)方益肝靈預(yù)防抗結(jié)核藥物致肝損傷的臨床療效顯著,可對(duì)其形成一定的保護(hù)功能,降低肝損傷的發(fā)生率,對(duì)其臨床療效的提高以及生活質(zhì)量的改善也有著積極的意義,具有在臨床上廣泛推廣的價(jià)值。
[Abstract]:Objective to study the clinical effect of compound Yiganling on preventing liver injury caused by antituberculotic drugs. Methods 80 cases of tuberculosis patients from April 2015 to June 2015 in our center were selected as the subjects of this study. . The participants were divided into two different groups, defined as control group and study group, with 40 patients in each group. Patients in control group were treated with general drugs. The patients in the study group were treated with compound Yiganling medicament for anti-liver injury. After the treatment, the clinical efficacy of the two groups of patients was compared. Results after treatment, the liver function index of the study group was significantly better than that of the control group. The levels of alt AST and TBIL in the study group were significantly lower than those in the control group (P 0.05). The incidence of liver function injury in the study group was significantly lower than that in the control group. Conclusion the clinical efficacy of compound Yiganling in preventing liver injury caused by anti-tuberculosis drugs is significant, which can form a certain protective function and reduce the incidence of liver injury. It has positive significance for the improvement of clinical curative effect and quality of life, and has the value of popularizing widely in clinic.
【作者單位】： 陜西省宜川縣疾病預(yù)防控制中心;
【分類號(hào)】：R52;R575
【正文快照】： 結(jié)核病是呼吸科較為常見(jiàn)的一種疾病,當(dāng)前治療往往通過(guò)抗結(jié)核藥物。抗結(jié)核藥物對(duì)于患者的身體健康也有很大的威脅的,為了降低抗結(jié)核的不良反應(yīng),本文選取2015年4月至2015年6月,我中心負(fù)責(zé)管理的80例結(jié)核病患者,研究組接受復(fù)方益肝靈藥劑治療,取得滿意效果,現(xiàn)將具體結(jié)果報(bào)道如下

【相似文獻(xiàn)】

相關(guān)期刊論文 前3條

1 劉健,叢文齊;復(fù)方益肝靈加丹參注射液治療慢性肝炎63例[J];中西醫(yī)結(jié)合肝病雜志;1996年03期

2 盧善亮;復(fù)方益肝靈治療病毒性肝炎及肝硬化146例療效觀察[J];藥學(xué)實(shí)踐雜志;1996年04期

3 ;[J];;年期

相關(guān)會(huì)議論文 前1條

1 卜建玲;黃學(xué)銳;高微微;;藥物預(yù)防抗結(jié)核藥物肝損害的療效觀察[A];中國(guó)防癆協(xié)會(huì)全國(guó)學(xué)術(shù)會(huì)議大會(huì)學(xué)術(shù)報(bào)告[C];2001年

，

本文編號(hào)：1386930